<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129321">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01747876</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011X2102</org_study_id>
    <nct_id>NCT01747876</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma</brief_title>
  <official_title>A Phase I, Multi-center, Open-label Study of LEE011 in Patients With Malignant Rhabdoid Tumors and Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      LEE011 is a small molecule inhibitor of CDK4/6.  LEE011 has demonstrated in vitro and in
      vivo activity in both tumor models.

      The primary purpose of this study is to determine the maximum tolerated dose (MTD) and/or
      recommended dose for expansion (RDE) in pediatric patients and to delineate a clinical dose
      to be used in future studies. This study will also assess the safety, tolerability, PK and
      preliminary evidence of antitumor activity of LEE011 in patients with MRT or neuroblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence rate of dose limiting toxicities (DLTs)</measure>
    <time_frame>cycle 1 = 28 days (from the time of first dose)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LEE011 as a single agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events (AEs)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LEE011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory values</measure>
    <time_frame>baseline, 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LEE011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in electrocardiograms (ECGs)</measure>
    <time_frame>baseline, 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LEE011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration time profiles</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize the PK of LEE001 and any clinically significant metabolites that may be identified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters including but not limited to AUCtau, Cmax, Tmax, CL/F, accumulation ration (Racc) and T1/2, acc</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize the PK of LEE001 and any clinically significant metabolites that may be identified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the anti-tumor activity of LEE011 by RECIST 1.1. In addition, for neuroblastoma, response by International neuroblastoma response criteria (INRC), for primary Central nervous system (CNS) tumors, response by Revised Assessment in Neuro-Oncology (RANO) Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration or response (DOR)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the anti-tumor activity of LEE011 by RECIST 1.1. In addition, for neuroblastoma, response by International neuroblastoma response criteria (INRC), for primary Central nervous system (CNS) tumors, response by Revised Assessment in Neuro-Oncology (RANO) Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) per RECIST 1.1</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the anti-tumor activity of LEE011. TTP per RECIST 1.1. In addition, for neuroblastoma, response by International neuroblastoma response criteria (INRC), for primary Central nervous system (CNS) tumors, response by Revised Assessment in Neuro-Oncology (RANO) Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Serious Adverse Events (SAEs)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LEE011.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Malignant Rhabdoid Tumors (MRT), Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>LEE011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>LEE011 is a small molecule inhibitor of CDK4/6.</description>
    <arm_group_label>LEE011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of MRT  or, neuroblastoma or in dose escalation part, other
             tumors with documented evidence of D-cyclin-CDK4/6-INK4a-Rb pathway abnormalities
             (dose escalation part only),

          -  Patients with CNS disease should be on stable doses of steroids for at least 7 days
             prior to first dose of LEE011 with no plans for escalation.

          -  In expansion part, patients must have at least one measurable disease as defined by
             RECIST v1.1.

          -  Patients must have a Lansky (≤ 16 years) or Karnofsky (&gt; 16 years) score of at least
             50.

        Exclusion Criteria:

          -  Prior history of QTc prolongation or QTcF &gt; 450 ms on screening ECG.

          -  Patients with the following laboratory values during screening:

               -  Serum creatinine &gt; 1.5 x upper limit of normal (ULN) for age

               -  Total bilirubin &gt;1.5 x ULN for age

               -  Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) &gt; 3 x
                  ULN for age; aspartate aminotransferase (AST)/serum glutamic oxaloacetic
                  transaminase(SGOT) &gt; 3 x ULN for age except in patients with tumor involvement
                  of the liver who must have AST/SGOT and ALT/SGPT ≤ 5 x ULN for age. For the
                  purpose of this study, the ULN for SGPT/ALT is 45 U/L.

          -  Patients who are currently receiving treatment with agents that are metabolized
             predominantly through CYP3A4/5 and have a narrow therapeutic window and/or agents
             that are known strong inducers or inhibitors CYP3A4/5 are prohibited. In particular,
             enzyme-inducing antiepileptic drugs (EIAEDs).

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may interfere with the interpretation of study results, and in the
             judgment of the investigator would make the patient inappropriate for the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco Dept of Pediatic Oncology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kresge</last_name>
      <phone>415-514-3658</phone>
      <email>Sharon.Kresge@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Dubois</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta Dept of Oncology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Garrett</last_name>
      <phone>404-785-3535</phone>
      <email>katherine.garrett@choa.org</email>
    </contact>
    <investigator>
      <last_name>Muna Qayed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute SC-7</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Pinches</last_name>
      <phone>617-632-6308</phone>
      <email>nathan_pinches@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Chi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Dept of Onc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Chamberlain</last_name>
      <phone>646-888-5716</phone>
      <email>chambee1@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Shakeel Modak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center Dept of Oncology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny T Thomas</last_name>
      <phone>513-636-9419</phone>
      <email>jenny.quinn@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>James Geller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia Dept of Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Devaney Camburn</last_name>
      <phone>267-426-9293</phone>
      <email>camburnd@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>John Maris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude's Children's Research Hospital Dept of Oncology</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Vest</last_name>
      <phone>901-595-2734</phone>
      <email>jennifer.vest@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Giles Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Dept Oncology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dione Froman</last_name>
      <phone>206-884-1214</phone>
      <email>dione.froman@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Julie Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2130</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>pediatric</keyword>
  <keyword>CDK4/6 inhibitor</keyword>
  <keyword>dose escalation</keyword>
  <keyword>malignant rhabdoid tumors</keyword>
  <keyword>MRT</keyword>
  <keyword>neuroblastoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
